Whole genome sequencing precision medicine strategy to shorten treatment for rifampicin-resistant tuberculosis (SMARTT): a pragmatic, randomised, single-blind phase 4 trial
Published in The Lancet Respiratory Medicine, 2026
This publication is available via DOI.
Recommended citation: Van Rie, A., Conceição, E.C., Ndebele, F., Wells, F., Paulse, A., Mekonnen, E.G., Ngarega, M., Trang, T.P.H., Bohlela, S., Sibeko, Z., Segwaba, P., Verboven, L., Heupink, T.H., Fuertes, M.D.D., Rennie, V., Dippenaar, A., Rigouts, L., Setlhare, L., Ogunbayo, A.E., VanderSpoel Van Dyk, A., Conradie, F., Maartens, G., Potgieter, S., Black, J., Fanampe, B., Abrams, S., Churchyard, G., Warren, R., & Charalambous, S. (2026) "Whole genome sequencing precision medicine strategy to shorten treatment for rifampicin-resistant tuberculosis (SMARTT): a pragmatic, randomised, single-blind phase 4 trial." The Lancet Respiratory Medicine. 14(6), 521–532.